Is there a role for therapeutic lobectomy for emphysema?

Vaughan, Paul; Oey, Inger; Nakas, Apostolos; Martin-Ucar, Antonio; Edwards, John; Waller, David
March 2007
European Journal of Cardio-Thoracic Surgery;Mar2007, Vol. 31 Issue 3, p486
Academic Journal
Abstract: Objective: The feasibility of performing a standard lobectomy in patients with non-small cell lung cancer (NSCLC) and severe heterogeneous emphysema whose respiratory reserve is outside standard operability guidelines has been described [Edwards JG, Duthie DJR, Waller DA. Lobar volume reduction surgery: a method of increasing the lung cancer resection rate in patients with emphysema. Thorax 2001;56:791–5; Korst RJ, Ginsberg RJ, Ailawadi M, Bains MS, Downey RJ, Rusch V, Stover D. Lobectomy improves ventilatory function in selected patients with severe COPD. Ann Thorac Surg 1998;66:898–902; Carretta A, Zannini P, Puglisi A, Chiesa G, Vanzulli A, Bianchi A, Fumagalli A, Bianco S. Improvement in pulmonary function after lobectomy for non-small cell lung cancer in emphysematous patients. Eur J Cardiothorac Surg 1999;15(5):602–7]. Postoperative lung function was better than predicted, attributable to the therapeutic benefit of deflation of the hemithorax. Our aim was to determine whether the physiological benefits of this approach were superior to conventional non-anatomical lung volume reduction surgery (LVRS) in similar patients. Methods: A retrospective review of a single surgeon''s experience identified 34 consecutive patients who underwent upper lobectomy for completely resected stage I–II NSCLC, and who had severe heterogeneous emphysema of apical distribution with a predicted postoperative FEV1 of less than 40%. Their perioperative characteristics, postoperative spirometry and survival of these cases were compared to 46 similar patients who underwent unilateral upper lobe LVRS during the same period. Results: Data expressed as median (range). LVRS patients were significantly younger (59 years [39–70] vs 67 years [48–79] p <0.001), with more severe airflow obstruction (FEV1 %pred 24 [12–60] vs 44 [17–54] p <0.001) and more heterogenous disease (‘Q’ score 4 [0.5–11.5] vs 7 [1–13] p =0.001) than the lobectomy group. No significant difference was found in median survival (88 vs 53 months, p =0.06). Lobectomy patients had a shorter air leak duration (5 days [2–36] vs 9 days [1–40], p =0.02) and hospital stay (8 days [3–63] vs 13 days [6–90] p =0.01). A significant correlation was found between pre-operative Q score and percentage improvement in FEV1 (r =−0.33, p =0.02). Conclusions: Lobectomy for lung cancer in patients in severe heterogenous chronic obstructive pulmonary disease is associated with similar improvement in airflow obstruction as conventional LVRS, but is associated with a shorter postoperative course. Lobectomy may therefore offer a therapeutic alternative to conventional LVRS in a selected population.


Related Articles

  • PET staging may reduce SCLC treatment costs.  // PharmacoEconomics & Outcomes News;5/26/2012, Issue 654, p6 

    The article discusses the effectiveness of positron emission tomography (PET) compared with conventional staging in the treatment of small-cell lung cancer, referencing a study by J. D. Ruben and colleagues published on the April 24, 2012 issue of the "Journal of Thoracic Oncology."

  • Role of positron emission tomography in mediastinal lymphatic staging of non-small cell lung cancer. Melek, Huseyin; Gunluoglu, Mehmet Zeki; Demir, Adalet; Akin, Hasan; Olcmen, Aysun; Dincer, Seyyit Ibrahim // European Journal of Cardio-Thoracic Surgery;Feb2008, Vol. 33 Issue 2, p294 

    Abstract: Objective: Positron emission tomography (PET) is used increasingly in staging of non-small cell lung cancer (NSCLC) as a non-invasive tool. The role of the PET in mediastinal lymphatic staging of NSCLC is not clear. We aimed to demonstrate the efficacy of PET in determining mediastinal...

  • Measurement of tumor volume by PET to evaluate prognosis in patients with advanced non-small cell lung cancer treated by non-surgical therapy. Hongjiang Yan; Renben Wang; Fen Zhao; Kunli Zhu; Shumei Jiang; Wei Zhao; Rui Feng // Acta Radiologica;Jul2011, Vol. 52 Issue 6, p646 

    Background: Patients with advanced non-small cell lung cancer (NSCLC) seem to have disparity in prognosis. Accurate prediction of prognosis could be useful in the future to predict individual risk and to develop more aggressive or alternative treatment strategies. Purpose: To evaluate the...

  • FDG-PET imaging for the staging and follow-up of small cell lung cancer. Schumacher, Tilmann; Brink, Ingo; Mix, Michael; Reinhardt, Michael; Herget, Georg; Digel, Werner; Henke, Michael; Moser, Ernst; Nitzsche, Egbert // European Journal of Nuclear Medicine;2001, Vol. 28 Issue 4, p483 

    Abstract. The staging procedures for small cell lung cancer do not differ appreciably from those for other forms of lung cancer. For practical purposes, the TNM stages are usually collapsed into a simple binary classification: limited disease and extensive disease. This study was performed to...

  • Non-small Cell Lung Cancer With Unsuspected Distant Metastasis To the Kidney Seen on PET/CT. Barry-Brooks, Marilyn; Yoo, Don C.; Chaump, Michael; Noto, Richard B. // Medicine & Health Rhode Island;May2012, Vol. 95 Issue 5, p144 

    The article presents a case study of a 72-year-old man diagnosed with Non Small Cell Lung Cancer (NSCLC) addicted to smoking complained about hoarseness during his physical examination. The Computed Tomography (CT) scan of his chest showed five centimeter left upper lobe mass invading the...

  • Mediastinal staging of lung cancer with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography and a dual-head coincidence gamma camera. Zimny, Michael; Hochstenbag, Monique; Lamers, Rob; Reinartz, Patrick; Cremerius, Uwe; ten Velde, Guul; Buell, Udalrich // European Radiology;Apr2003, Vol. 13 Issue 4, p740 

    The aims of the present study were (a) to evaluate mediastinal staging in patients with lung cancer with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) using a coincidence gamma camera (hybrid PET) in comparison with dedicated positron emission tomography (PET) and computed tomography (CT), and...

  • Prognostic value of [[sup 18] F]FDG-PET imaging in small cell lung cancer. Pandit, Neeta; Gonen, Mithat; Krug, Lee; Larson, Steven M. // European Journal of Nuclear Medicine & Molecular Imaging;2003, Vol. 30 Issue 1, p78 

    Positron emission tomography (PET) utilizing fluorine-18 fluorodeoxyglucose (FDG) has been used in the evaluation of non-small cell lung cancer (NSCLC). Recently its use in the staging of small cell lung cancer (SCLC) has been reported. However, the prognostic value of FDG-PET imaging in SCLC...

  • Rola pozytonowej tomografii emisyjnej (PET) w planowaniu radioterapii. Cytawa, Wojciech // Polish Oncology / Onkologia Polska;2012, Vol. 15 Issue 3, p103 

    The effectiveness of radiotherapy is highly dependent on precise target volume delineation. Apart from computed tomography which is a "gold standard" in radiotherapy planning,: other imaging modalities, such as positron emission tomography (PET), begin to play an important role in this process....

  • PET--CT in lung cancer: data discrepancies. Paredes, Jose M.; Mehta, Jayesh // Thorax;Dec2011, Vol. 66 Issue 12, p1092 

    A letter to the editor is presented in response to the Danish study of positron emission tomography (PET)-computer tomography (CT) versus conventional staging (CS) in non-small cell lung cancer.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics